JAK2 activating mutations in MPN were first identified in 2005 with the discovery of a point mutation leading to a JAK2-V617F mutant protein that exhibits elevated activity, leading to deregulated signaling and hypersensitivity to cytokines [9–12]. Here, JAK2 is linked to myeloproliferative neoplasm.